<DOC>
	<DOCNO>NCT01683292</DOCNO>
	<brief_summary>In first study inhale apomorphine Parkinson 's disease patient , primary objective find minimum efficacious dose apomorphine useful rescue patient 'off ' period . Safety , tolerability pharmacokinetics inhale apomorphine assess study .</brief_summary>
	<brief_title>Single-Centre Study VR040 ( Inhaled Apomorphine ) Idiopathic Parkinson 's Disease</brief_title>
	<detailed_description>Objectives :</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Apomorphine</mesh_term>
	<criteria>1 . Patients establish idiopathic PD ( via fulfilment Steps 1 2 UK Brain Bank Criteria ) , least 3 year duration prior study entry , specific optimise antiParkinson medication ( levodopa and/or dopamine agonist ) , motor fluctuation . 2 . Patients modify Hoehn Yahr disease severity score 2 4 `` '' state . 3 . Men woman age 30 year . 4 . Patients sign dated write valid consent obtain prior participation . 5 . Female patient must nonchildbearing potential ( ie , physiologically incapable become pregnant , include female postmenopausal ) childbearing potential negative pregnancy test ( urine serum ) screening . 6 . Patients experience motor fluctuation recognisable `` '' period control motor symptom , assess motor fluctuation questionnaire ( patient report least 1 `` Yes '' response question motor fluctuation questionnaire ) . 7 . Patient willing able comply study procedure . 1 . Patients participate trial investigational product within 3 month prior randomisation Visit 2 . 2 . Patients serious uncontrolled disease include serious psychological disorder likely interfere study and/or likely cause death within 6 month study completion . 3 . Patients previous intolerance apomorphine . 4 . Patients previous significant complication oral dopamine agonist therapy include hospitalisation follow dopamine agonist introduction and/or development hallucination adverse neuropsychiatric feature follow introduction sc apomorphine . 5 . Women lactate , pregnant , childbearing potential use reliable contraceptive method . 6 . Patients know HIV active chronic hepatitis B C infection . 7 . Patients clinically significant abnormality follow review screen laboratory data full physical examination . 8 . Patients , Investigator 's opinion , unsuitable study reason . 9 . Patients clinically significant blood test abnormality previous medical history/intercurrent illness may compromise safety patient study . 10 . Patients major ECG abnormality ( judged Investigator ) . 11 . Patients FEV1 &lt; 65 % . 12 . Patients show postural decrease systolic blood pressure ( BP ) &gt; 20 mm Hg , show significant clinical symptom associate orthostatic hypotension . 13 . Patients persistent elevation BP , average systolic reading 160 mm Hg average diastolic reading 100 mm Hg . 14 . Patients take anabolic steroid , traditional antipsychotic ( unless low dose ) , antiemetic domperidone . 15 . Patients take agent 5HT3 antagonist class include ondansetron , granisetron , dolasetron , palonosetron , alosetron . 16 . Patients exist cancer remission le 5 year . 17 . Patients evidence ( ascertained examination , test history ) indicate cardiovascular , gastrointestinal tract , liver , kidney , central nervous system , pulmonary system , bone marrow disorder Investigator 's opinion compromise patient safety . 18 . Patients known nonresponders apomorphine treatment `` '' episode . 19 . Patients history drug alcohol abuse 12 month prior entry . 20 . Patients history clinically significant allergy VR040 formulation constituent ( include lactose opioids ) domperidone . 21 . Patients sign symptom suggestive schizophrenia , dementia , `` Parkinson plus '' syndrome , unstable systemic disease</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>apomorphine</keyword>
	<keyword>inhale</keyword>
	<keyword>motor fluctuation</keyword>
</DOC>